Have a feature idea you'd love to see implemented?
Let us know!
FHTX Foghorn Therapeutics Inc
Price (delayed)
$4.24
Market cap
$235.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.92
Enterprise value
$215.4M
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The
Highlights
Foghorn Therapeutics's EPS has increased by 22% YoY
The company's debt fell by 17% YoY and by 4.5% QoQ
The equity has plunged by 98% from the previous quarter but it has soared by 51% YoY
The net income is up by 12% YoY but it is down by 6% from the previous quarter
FHTX's gross profit is down by 27% since the previous quarter and by 22% year-on-year
The company's revenue fell by 27% QoQ and by 22% YoY
Key stats
What are the main financial stats of FHTX
Market
Valuations
Earnings
Shares outstanding
55.59M
Market cap
$235.71M
Enterprise value
$215.4M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
10.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.44
Revenue
$25.52M
Gross profit
$25.52M
Net income
-$91.22M
EBIT
-$89.24M
EBITDA
-$80.38M
Free cash flow
-$103.89M
Per share
Balance sheet
Liquidity
EPS
-$1.92
EPS diluted
-$1.92
Free cash flow per share
-$1.66
Book value per share
-$0.51
Revenue per share
$0.41
TBVPS
$4.93
Total assets
$308.37M
Total liabilities
$336.66M
Debt
$39.07M
Equity
-$28.29M
Working capital
$214.41M
Debt to equity
-1.38
Current ratio
4.77
Quick ratio
4.74
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
-315%
Gross margin
100%
Net margin
-357.5%
Operating margin
-408.1%
Return on assets
-31%
Return on equity
N/A
Return on invested capital
-46.7%
Return on capital employed
-35.5%
Return on sales
-349.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FHTX stock price
How has the Foghorn Therapeutics stock price performed over time
Intraday
-2.97%
1 week
-9.59%
1 month
-20%
1 year
-19.39%
YTD
-10.17%
QTD
-10.17%
Financial performance
How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$25.52M
Gross profit
$25.52M
Operating income
-$104.14M
Net income
-$91.22M
Gross margin
100%
Net margin
-357.5%
FHTX's operating margin is down by 47% QoQ and by 16% YoY
The company's net margin fell by 46% QoQ and by 13% YoY
FHTX's gross profit is down by 27% since the previous quarter and by 22% year-on-year
The company's revenue fell by 27% QoQ and by 22% YoY
Growth
What is Foghorn Therapeutics's growth rate over time
Valuation
What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
10.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.44
Foghorn Therapeutics's EPS has increased by 22% YoY
The equity has plunged by 98% from the previous quarter but it has soared by 51% YoY
FHTX's P/S is 95% lower than its 5-year quarterly average of 196.5 and 13% lower than its last 4 quarters average of 11.9
The company's revenue fell by 27% QoQ and by 22% YoY
Efficiency
How efficient is Foghorn Therapeutics business performance
Foghorn Therapeutics's ROS has decreased by 47% from the previous quarter and by 13% YoY
FHTX's return on invested capital is down by 35% year-on-year and by 7% since the previous quarter
The ROA has contracted by 7% YoY and by 6% from the previous quarter
Dividends
What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FHTX.
Financial health
How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 8% lower than its total liabilities
The current ratio has contracted by 16% from the previous quarter and by 6% YoY
FHTX's quick ratio is down by 16% since the previous quarter and by 6% year-on-year
The equity has plunged by 98% from the previous quarter but it has soared by 51% YoY
The debt to equity has shrunk by 68% YoY but it has soared by 52% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.